> Detailanzeige

Peltenburg, Puck J; van den Heuvel, Lieke M; Kallas, Dania; Bell, Cheyanne; Denjoy, Isabelle; Behr, Elijah R; Field, Ella; Kammeraad, Janneke A E; Yap, Sing-Chien; Probst, Vincent; Ackerman, Michael J; Blom, Nico A; Wilde, Arthur A M; Clur, Sally-Ann B; van der Werf, Christian

Insights into adherence to medication and lifestyle recommendations in an international cohort of patients with catecholaminergic polymorphic ventricular tachycardia

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Insights into adherence to medication and lifestyle recommendations in an international cohort of patients with catecholaminergic polymorphic ventricular tachycardia
  • Beteiligte: Peltenburg, Puck J; van den Heuvel, Lieke M; Kallas, Dania; Bell, Cheyanne; Denjoy, Isabelle; Behr, Elijah R; Field, Ella; Kammeraad, Janneke A E; Yap, Sing-Chien; Probst, Vincent; Ackerman, Michael J; Blom, Nico A; Wilde, Arthur A M; Clur, Sally-Ann B; van der Werf, Christian
  • Erschienen: Oxford University Press (OUP), 2024
  • Erschienen in: Europace
  • Sprache: Englisch
  • DOI: 10.1093/europace/euae044
  • ISSN: 1099-5129; 1532-2092
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Aims</jats:title> <jats:p>In patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare inherited arrhythmia syndrome, arrhythmic events can be prevented by medication and lifestyle recommendations. In patients who experience breakthrough arrhythmic events, non-adherence plays an essential role. We aimed to investigate the incidence and potential reasons for non-adherence to medication and lifestyle recommendations in a large, international cohort of patients with CPVT.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods and results</jats:title> <jats:p>An online multilingual survey was shared with CPVT patients worldwide by their cardiologists, through peer-recruitment, and on social media from November 2022 until July 2023. Self-reported non-adherence was measured using the validated Medication Adherence Rating Scale (MARS) and a newly developed questionnaire about lifestyle. Additionally, validated questionnaires were used to assess potential reasons for medication non-adherence. Two-hundred-and-eighteen patients completed the survey, of whom 200 (92%) were prescribed medication [122 (61%) female; median age 33.5 years (interquartile range: 22–50)]. One-hundred-and-three (52%) were prescribed beta-blocker and flecainide, 85 (43%) beta-blocker, and 11 (6%) flecainide. Thirty-four (17%) patients experienced a syncope, aborted cardiac arrest or appropriate implantable cardioverter defibrillator shock after diagnosis. Nineteen (13.4%) patients were exercising more than recommended. Thirty (15%) patients were non-adherent to medication. Female sex [odds ratio (OR) 3.7, 95% confidence interval (CI) 1.3–12.0, P = 0.019], flecainide monotherapy compared to combination therapy (OR 6.8, 95% CI 1.6–31.0, P = 0.010), and a higher agreement with statements regarding concerns about CPVT medication (OR 1.2, 95% CI 1.1–1.3, P &amp;lt; 0.001) were independently associated with non-adherence.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>The significant rate of non-adherence associated with concerns regarding CPVT-related medication, emphasizes the potential for improving therapy adherence by targeted patient education.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang